Treatment of different phenotypes of chronic obstructive pulmonary disease

The aim of the study was to investigate COPD phenotypes in order to improve treatment efficacy of occupational COPD and comorbidity of COPD and hypertension.

Methods. This singlecenter observational study involved 97 patients with occupational COPD (according to GOLD 2011 criteria) exposed to chemicals (n = 42) or dusts (n = 55) and 103 patients with of COPD and hypertension (according to ESH/ESC 2013 criteria). Comparison groups included patients with 73 smokers with COPD and 99 patients with COPD without hypertension. Phenotypic features of occupational COPD caused by different workrelated factors and comorbidity of COPD and hypertension were described. The obtained results underlie the treatment programs for each group. A singlecenter openlabel comparative study was conducted to evaluate the efficacy of this approach.

Results. Beclometasone/formoterol combination and tiotropium were used for therapy of COPD related to chemical exposure; indacaterol, glycopyrronium and budesonide were used for therapy of dustrelated COPD. Patients with comorbidity of COPD and hypertension were treated with budesonide/formoterol combination and aclidinium. Coprimary endpoints were exacerbation rate and change of FEV1pred. Treatment with beclometasone/formoterol and tiotropium decreased the exacerbation rate, increased FEV1, improved symptoms, and decreased pulmonary hypertension in patients with COPD related to chemical exposure. Treatment with indacaterol, glycopyrronium and budesonide decreased the exacerbation rate, increased FEV1, improved symptoms, and decreased pulmonary hypertension in patients with dustrelated COPD. Treatment with budesonide/formoterol and aclidinium improved lung function, decreased pulmonary hypertension and improved symptoms in patients with comorbidity of COPD and hypertension.

Conclusion. Different risk factors of COPD could be considered as markers of therapeutic response.

1. Chuchalin A.G., Aysanov Z.R., Avdeev S.N. et al. Russian Respiratory Society. Federal Clinical Guidelines on Diagnosis and Management of Chronic Obstructive Pulmonary Disease. Available at: http://www.pulmonology.ru/publications/guide.php (in Russian).

2. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and preven tion of chronic obstructive pulmonary disease (revised 2016). Available at: http://www.goldcopd.org/guidelinesglob alstrategyfordiagnosismanagement.html. 2016. Accessed July 20, 2016.

3. Kornmann O., Dahl R., Centanni S. et al. Oncedaily indacaterol versus twicedaily salmeterol for COPD: a placebo controlled comparison. Eur. Respir. J. 2011; 37 (2): 273–279. DOI: 10.1183/09031936.00045810.

4. Marin J.M., Beeh K.M., Clemens A. et al. Early bronchodilator action of glycopyrronium versus tiotropium in moderatetosevere COPD patients: a crossover blinded randomized study (Symptoms and Pulmonary function in the moRnING). Int. J. Chron. Obstruct. Pulm. Dis. 2016; 11: 1425–134.

5. Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108 (8): 1153–1162. DOI: http://dx.doi.org/10.1016/j.rmed.2014.05.013.

6. Agusti A., Bel E., Thomas M. et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur. Respir. J. 2016; 47 (2): 410–419. DOI: 10.1183/13993003.013592015.

7. Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/longacting β2 agonist efficacy in COPD. Thorax. 2016; 71 (2): 118– 125.

8. Suissa S., Dell'Aniello S., Ernst P. Longterm natural history of chronic obstructive pulmonary disease: severe exacer bations and mortality. Thorax. 2012; 67 (11): 957–963. DOI:10.1136/thoraxjnl2011201518.

9. Miravitlles M., SolerCataluna J.J., Calle M., Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice Eur. Respir. J. 2013; 41 (6): 1252–1256.

10. Rennard S.I., Calverley P.M., Goehring U.M. et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir. Res. 2011; 12: 18.

11. Chuchalin A.G., Shpagina L.A., Vasil'eva O.S. et al. Occupational Chronic Obstructive Pulmonary Disease. National Guidelines. Moscow: GEOTAR; 2015: 293–338 (in Russian).

12. Rodríguez E., Ferrer J., Zock J.P. et al. Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients. PLoS One. 2014; 9 (2): e88426.

13. Brüske I., Thiering E., Heinrich J. et al. Biopersistent granular dust and chronic obstructive pulmonary disease: a systematic review and metaanalysis. PLoS One. 2013; e80977.

14. Shpagina L.A., Voevoda M.I., Kotova O.S. et al. Occupational chronic obstructive pulmonary disease. Byulleten' fiziologii i patologii dykhaniya. 2013; (49): 8–15 (in Russian).

15. Miller J., Edwards L.D., Agustí A. et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 2013; 107 (9): 1376–1384.

16. Shrikrishna D., Astin R., Kemp P.R., Hopkinson N.S. Reninangiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin. Sci. (Lond). 2012; 123 (8): 487–498.

17. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013; 31 (7): 1281–1357.

18. Miller M.R., Hankinson J., Brusasco V. et al. ATS/ERS Task Force. Standardisation of spirometry. Eur. Respir. J. 2005; 26 (2): 319–338.

19. Rossi A., Zanardi E., Poletti V., Cazzola M. Clinical role of dual bronchodilation with an indacaterolglycopyrronium combination in the management of COPD: its impact on patientrelated outcomes and quality of life. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1383–1392.

20. Beier J., Kirsten A.M., Mróz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderatetosevere chronic obstructive pulmonary disease: results from a 6week, randomized, controlled Phase IIIb study. COPD. 2013; 10 (4): 511–522.